- STAAR Surgical manufactures and sells implantable collamer lenses (ICLs) for patients suffering from myopia or presbyopia.
- The company only makes ~3.5% in the US market and its largest market shares are in APAC - but STAAR is chasing an approval for its latest products in US.
- STAAR's shares have gained 211% since March - presumably on the promise of US approval - but trade at a huge premium to sales and net income.
- At current price of $79.5 you have to be brave to back STAAR - but the addressable market is large enough to justify taking the plunge.
- This is a long-term (10-15 year) growth story in my view. Investors looking to invest short-term may be better off waiting for a cheaper entry point.
For further details see:
STAAR Surgical: Peak Share Price Suggests Caution, But Long-Term Growth Story Is Persuasive